IBAB.BR
BuyFull HouseIon Beam Applications SA · Healthcare · Belgium · $567M · Avg Vol: $360K/d
Full House: Strong business, sensible price, market agrees. The rare full house.
ABOUT ION BEAM APPLICATIONS SA
Read
Ion Beam Applications SA is the global leader in advanced proton therapy systems used for highly targeted cancer treatment, as well as industrial sterilization and radiopharmaceutical equipment. The company competitive moat is built on its cutting-edge particle accelerator technology, extensive patent portfolio, and high switching costs associated with complex medical installations. It operates as a dominant high-tech medical device manufacturer with a substantial global installed base.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 361.3M | 466.7M | 498.2M | 620.2M | 19.7% | 638.3M | 633.4M | 642.6M | 1.8% |
| EPS (EUR) | 0.21 | -0.31 | 0.32 | 0.43 | 27.9% | 0.81 | 0.79 | 1.10 | 59.5% |
| Shares | 29.2M | 29.2M | 29.2M | 29.4M | +0.7% | 29.0M | — | — | — |
| Debt | 40.9M | 41.6M | 43.7M | 116.9M | 42.0% | 118.7M | — | — | — |
| Equity | 116.0M | 106.2M | 110.9M | 127.2M | 3.1% | — | — | — | — |
| Op CF | 21.7M | -19.8M | -10.6M | -25.7M | — | 4.5M | — | — | — |
| Inv CF | -19.1M | -13.3M | -13.8M | -35.3M | — | — | — | — | — |
| Fin CF | -41.5M | -14.4M | -12.2M | 56.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IBAB.BR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IBAB.BR | Ion Beam Applications SA(you) | $567M | 71 | Buy |
| SEQUA.BR | Sequana Medical NV | $54M | 13 | Strong Sell |
| LKFT | Lakefront Biotherapeutics NV | $1.9B | 68 | Buy |
| FAGR.BR | Fagron NV | $1.9B | 83 | Strong Buy |
| AGMB | AgomAb Therapeutics NV | $649M | 14 | Strong Sell |
| HYL.BR | Hyloris Pharmaceuticals SA | $143M | 14 | Strong Sell |
| NYXH | Nyxoah SA | $163M | 10 | Strong Sell |
| UCB.BR | UCB SA | $47.8B | 79 | Buy |
| TUB.BR | Financière de Tubize SA | $9.6B | 29 | Sell |
| MDXH | MDxHealth SA | $69M | 13 | Strong Sell |
Peer medians: ROE -8.3% · P/E 18.0x · Gross margin 62.9%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.